Valbenazine, a Huntington therapy, shows notable, long-term benefits in the KINECT-HD open-label extension.

Published Date: 19 Nov 2023

After almost a year of treatment, valbenazine was well tolerated and the severity of the chorea showed a clinically significant improvement, much like the double-blind study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

AACR: American Association for Cancer Research

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot